FMP
Context Therapeutics Inc.
CNTX
NASDAQ
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
1.3 USD
-0.11 (-8.46%)
About
ceo
Mr. Martin A. Lehr
sector
Healthcare
industry
Biotechnology
website
https://www.contexttherapeutics.com
exchange
NASDAQ
Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integ...
CIK
0001842952
ISIN
US21077P1084
CUSIP
21077P108
Address
2001 Market Street
Phone
267 225 7416
Country
US
Employee
5
IPO Date
Oct 20, 2021
Summary
CIK
0001842952
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
21077P108
ISIN
US21077P1084
Country
US
Price
1.3
Beta
2.17
Volume Avg.
56.59k
Market Cap
20.76M
Shares
-
52-Week
0.47-1.69
DCF
0.91
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.87
P/B
-
Website
https://www.contexttherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CNTX News
It looks like there's no news available.
